Cargando…

Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues

Detalles Bibliográficos
Autores principales:	Vaag, Allan, Lund, Sørens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioScientifica 2012
Materias:	Erratum: THERAPY OF ENDOCRINE DISEASE
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3547318/ http://dx.doi.org/10.1530/EJE-11-0022e

Ejemplares similares

THERAPY OF ENDOCRINE DISEASE: Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues
por: Vaag, Allan, et al.
Publicado: (2012)

Impact of a Novel Insulin Management Service on Non-insulin Pharmaceutical Expenses
por: Schneider, John E., et al.
Publicado: (2018)

Intensification of Insulin Therapy for Type 2 Diabetic Patients in Primary Care: Basal-Bolus Regimen Versus Premix Insulin Analogs: When and for whom?
por: Mosenzon, Ofri, et al.
Publicado: (2013)

Cost Effectiveness of Insulin Glargine versus Neutral Protamin Hagedorn Insulin in the Treatment of Type 2 Diabetes Patients in Turkey
por: Satman, Ilhan, et al.
Publicado: (2013)

Is There Evidence to Support Use of Premixed or Prandial Insulin Regimens in Insulin-Naive or Previously Insulin-Treated Type 2 Diabetic Patients?
por: Yki-Järvinen, Hannele, et al.
Publicado: (2013)

A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study
por: Gordon, J, et al.
Publicado: (2010)

Combination Therapy With Premixed & Basal Insulin Analogues in Asian Indians With Type 2 Diabetes
por: Srivastava, Brijendra Kumar, et al.
Publicado: (2021)

A Pragmatic Clinical Trial to Compare the Real-World Effectiveness of V-Go versus Standard Delivery of Insulin in Patients with Advanced Type 2 Diabetes
por: Cziraky, Mark J., et al.
Publicado: (2019)

Cost-effectiveness of Simple Insulin Infusion Devices Compared to Multiple Daily Injections in Uncontrolled Type 2 Diabetics in the United States Based on a Simulation Model
por: Wahlqvist, Peter, et al.
Publicado: (2018)

Patient Preference for Once-Weekly Dosing in Type 2 Diabetes Mellitus in Japan
por: Sen, Rohini, et al.
Publicado: (2016)

How Do Diabetes Models Measure Up? A Review of Diabetes Economic Models and ADA Guidelines
por: Govan, Lindsay, et al.
Publicado: (2015)

Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes
por: Currie, Craig J., et al.
Publicado: (2013)

Role of premixed insulin analogues in the treatment of patients with type 2 diabetes mellitus: A narrative review
por: Elizarova, Svetlana, et al.
Publicado: (2014)

Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension
por: Mathieu, Chantal, et al.
Publicado: (2013)

Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis
por: Moon, Shinje, et al.
Publicado: (2021)

Influence of Liver Triglycerides on Suppression of Glucose Production by Insulin in Men
por: Jin, Eunsook S., et al.
Publicado: (2015)

Unmet Needs in the Management of Type 2 Diabetes Mellitus Patients Starting Insulin Therapy with Basal or Premix Insulin in Routine Clinical Practice in Serbia
por: Beljić Živković, Teodora M., et al.
Publicado: (2018)

Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial
por: Lundby-Christensen, Louise, et al.
Publicado: (2016)

Advancing Therapy in Suboptimally Controlled Basal Insulin–Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial
por: Rosenstock, Julio, et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of insulin glargine–insulin glulisine basal-bolus and twice-daily premixed analog insulin in type 1 diabetes mellitus patients during three standardized meals
por: Lamos, Elizabeth Mary, et al.
Publicado: (2015)

Cost Savings and Reduced Health Care Utilization Associated with Participation in a Digital Diabetes Prevention Program in an Adult Workforce Population
por: Sweet, Cynthia Castro, et al.
Publicado: (2020)

Comparison of Basal-Bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes
por: Bellido, Virginia, et al.
Publicado: (2015)

Basal-bolus or premixed? Shedding light on optimal insulin regime for type 1 diabetes
por: Louise Walton, Emma
Publicado: (2018)

Basal-bolus Therapy in Patients with Type 2 Diabetes Mellitus in the UK: Patient Characteristics, Treatment Patterns and the Effect of Switching to Premixed Insulin
por: van Brunt, Kate, et al.
Publicado: (2016)

ARISE—a prospective, non-interventional, single-arm study assessing clinical parameters associated with the use of insulin degludec/insulin aspart in patients with type 2 diabetes in real-world settings: rationale and design
por: Fulcher, Gregory R., et al.
Publicado: (2021)

Erratum to: Adding Prandial Insulin to Basal Insulin Plus Oral Antidiabetic Drugs in Chinese Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Single-Arm Study
por: Jin, Yujing, et al.
Publicado: (2017)

Sexual Differences in response to Mid- or Low-Premixed Insulin Analogue in Patients with Type 2 Diabetes
por: Liu, Bing-li, et al.
Publicado: (2020)

ODP264 An Unusual Etiology of Hypothyroidism and New-Onset Insulin-Dependent Diabetes: A Rare Side Effect of Opdivo
por: Alchalabi, Halah, et al.
Publicado: (2022)

Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial
por: Giugliano, Dario, et al.
Publicado: (2021)

The metabolic and mitogenic properties of basal insulin analogues
por: Tennagels, Norbert, et al.
Publicado: (2013)

Practical Guidance on the Use of Premix Insulin Analogs in Initiating, Intensifying, or Switching Insulin Regimens in Type 2 Diabetes
por: Wu, Ted, et al.
Publicado: (2015)

Clinical study of treatment switching from premixed insulin to basal insulin combined with oral hypoglycemic drugs in patients with type 2 diabetes
por: Zhang, Ying, et al.
Publicado: (2014)

The efficacy and safety of combined GLP-1RA and basal insulin therapy among inadequately controlled T2D with premixed insulin therapy
por: Liu, Jhih-Syuan, et al.
Publicado: (2023)

A Real-World, Observational Study of the Initiation, Use, and Effectiveness of Basal-Bolus or Premixed Insulin in Japanese People with Type 2 Diabetes
por: Miyoshi, Hideaki, et al.
Publicado: (2021)

Basal insulin analogues in the treatment of diabetes mellitus: What progress have we made?
por: Kalra, Sanjay
Publicado: (2015)

Transitioning from basal–bolus or premix insulin therapy to a combination of basal insulin and glucagon‐like peptide‐1 receptor agonist in people with type 2 diabetes
por: Mehta, Roopa, et al.
Publicado: (2022)

PSUN181 Diabetes-related outcomes following use of basal-bolus insulin vs. premixed insulin in a VA population with Type 2 diabetes: A retrospective chart review.
por: Izuora, Kenneth, et al.
Publicado: (2022)

Insulin Icodec Weekly: A Basal Insulin Analogue for Type 2 Diabetes
por: Bajaj, Harpreet S, et al.
Publicado: (2023)

Effects of switching from prandial premixed insulin therapy to basal plus two times bolus insulin therapy on glycemic control and quality of life in patients with type 2 diabetes mellitus
por: Ito, Hiroyuki, et al.
Publicado: (2014)

PMON01 Alpelisib (PI3-K Inhibitor) Induced Severe Insulin Resistance Complicated by Diabetic Ketoacidosis (DKA) with Rapid Reversal Following Discontinuation: A Case Report
por: Lloyd, Jacob, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mksidk8tcdjc7dgetvdhc8othr